8-K: Theriva Biologics Receives FDA Guidance on Phase 3 Study Design for Pancreatic Cancer Treatment

Theriva Biologics announced positive feedback from the FDA regarding the design of a Phase 3 clinical trial for their lead candidate VCN-01 in combination with chemotherapy for metastatic pancreatic cancer.

Summary

• Theriva Biologics had a Type D meeting with the FDA to discuss the design of a Phase 3 clinical study for VCN-01, a treatment for metastatic pancreatic adenocarcinoma (PDAC).
• The FDA advised against expanding the ongoing VIRAGE Phase 2b study into Phase 3, recommending a stand-alone Phase 3 study instead.
• The FDA generally agreed with Theriva's proposed Phase 3 study design, suggesting that additional chemotherapy would complicate the study.
• The FDA provided guidance on statistical elements for confirmatory studies, including sample size estimation and data analysis populations.
• The company has completed target enrollment for the VIRAGE Phase 2b study, which is evaluating VCN-01 with gemcitabine/nab-paclitaxel as a first-line therapy for PDAC.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the FDA's agreement on the Phase 3 study design, but there are still risks and uncertainties associated with clinical trials and regulatory approvals.

Positives

• The FDA's feedback supports the progression of VCN-01 towards a Phase 3 study.
• The FDA's agreement on the study design simplifies the path forward for VCN-01 development.
• The completion of target enrollment in the VIRAGE Phase 2b study is a positive milestone.
• The FDA's guidance on statistical elements will help ensure a robust Phase 3 study.

Negatives

• The FDA advised against expanding the current Phase 2b study into a Phase 3 study, requiring a new stand-alone study.
• The company will need to conduct an additional meeting with the FDA to discuss the details of the proposed Phase 3 study protocol.

Risks

• The company's ability to effectively design the Phase 3 study protocol is critical.
• There is a risk that the company may not be able to reach clinical milestones as anticipated.
• The product candidates may not demonstrate safety and effectiveness.
• The company may not be able to obtain regulatory approval for commercialization.
• There is a risk of competition from other companies in the same space.

Future Outlook

The company plans to request an additional meeting with the FDA after the completion of the VIRAGE study to discuss the details of the proposed confirmatory Phase 3 study protocol. The company aims to maximize its ability to provide a new therapeutic option to patients suffering from pancreatic cancer.

Management Comments

• Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, stated that the FDA's advice is critical as the VIRAGE study has entered final patient follow-up and they are actively planning the next steps in VCN-01 development.
• Shallcross also mentioned that the feedback from the FDA and European regulatory agencies will facilitate the design of a Phase 3 study protocol that is expected to maximize their ability to provide a new therapeutic option to patients suffering this terrible disease.

Industry Context

This announcement is significant as it provides clarity on the regulatory pathway for VCN-01, a novel oncolytic adenovirus, in the treatment of pancreatic cancer, a disease with high unmet medical need. The FDA's guidance helps Theriva Biologics streamline its development process and potentially accelerate the availability of a new treatment option.

Comparison to Industry Standards

• The FDA's guidance on statistical elements aligns with industry best practices for confirmatory clinical studies.
• The decision to pursue a stand-alone Phase 3 study is a common approach for pivotal trials in oncology.
• The use of gemcitabine/nab-paclitaxel as a standard-of-care chemotherapy is consistent with current treatment protocols for pancreatic cancer.
• Other companies developing treatments for pancreatic cancer, such as Celgene (now part of Bristol Myers Squibb) with Abraxane (nab-paclitaxel) and Eli Lilly with Gemzar (gemcitabine), have also focused on combination therapies.

Stakeholder Impact

• Shareholders may view the FDA's guidance as a positive step towards potential commercialization of VCN-01.
• Patients with pancreatic cancer may benefit from a new treatment option if VCN-01 is successful in clinical trials.
• Employees of Theriva Biologics will be involved in the planning and execution of the Phase 3 study.

Next Steps

• The company will request an additional meeting with the FDA to discuss the details of the proposed Phase 3 study protocol.
• The company will continue to analyze data from the VIRAGE Phase 2b study.
• The company will design and initiate the stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel.

Key Dates

Keywords

VCN-01, pancreatic cancer, FDA, Phase 3 clinical trial, oncolytic adenovirus, metastatic PDAC, chemotherapy, VIRAGE study, clinical study, Theriva Biologics